Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
22 aug 2016 - 22:00
Statutaire naam
Galapagos NV
Titel
FINCH filgotinib Phase 3 program initiated in rheumatoid arthritis
Bericht
• Three studies addressing a broad population of patients with active rheumatoid arthritis
• Filgotinib 100 mg and 200 mg, once daily dosing in males and females worldwide in combination- and as monotherapy
Mechelen, Belgium; 22 August 2016 - Galapagos NV (Euronext & NASDAQ: GLPG) reports the initiation of the FINCH global Phase 3 program investigating the efficacy and safety of 100 mg and 200 mg filgotinib once daily, in rheumatoid arthritis (RA) patient populations, ranging from early stage to biologic-experienced patients.
Datum laatste update: 27 december 2025